Pazopanib in the treatment of soft tissue sarcoma

References

• Sinha S. Diagnosis and management of soft tissue sarcoma. BMJ341, C7170 (2010).
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J. Clin. Oncol.27(19), 3126–3132 (2009).
   PubMed Web of Science ®Google Scholar
• Clark MA, Fischer C, Judson I et al. Soft-tissue sarcomas in adults. N. Engl. J. Med.353, 701–711 (2005).
   PubMed Web of Science ®Google Scholar
• Brennan MF, Singer S, Maki RG. Sarcomas of the soft tissue and bone. In: Cancer: Principles and Practice of Oncology (Volumes 1 & 2), (8th Edition). DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 1741–1833 (2008).
   Google Scholar
• Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer91(10), 1914–1926 (2001).
   PubMed Web of Science ®Google Scholar
• Teixeira LEM, Vilela JC, De Araujo ID. Prognostic factors in soft tissue sarcoma. In: Soft Tissue Tumors. Derbel F (Ed.). InTech, Rijeka, Croatia, 255–262 (2011).
   Google Scholar
• Vraa S, Keller J, Nielsen OS et al. Prognostic factors in soft tissue sarcomas: the Aarhus experience. Eur. J. Cancer34(12), 1876–1882 (1998).
   PubMedGoogle Scholar
• Lietman SA. Soft-tissue sarcomas: overview of management, with a focus on surgical treatment considerations. Cleveland Clin. J. Med.77(Suppl. 1), S13–S17 (2010).
   PubMedGoogle Scholar
• Casali PG, Blay JY. Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), V198–V203 (2010).
   PubMed Web of Science ®Google Scholar
• Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J. Clin. Oncol.21, 2719–2725 (2003).
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist10, 833–841 (2005).
   PubMed Web of Science ®Google Scholar
• Tascilar M, Loos WJ, Seynaeve C et al. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist12, 1351–1360 (2007).
   PubMedGoogle Scholar
• Antman K, Crowley J, Balcerzak SP et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol.11(7), 1276–1285 (1993).
   PubMed Web of Science ®Google Scholar
• Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann. Oncol.22, 1266–1272 (2011).
   PubMed Web of Science ®Google Scholar
• Van Oosterom AT, Verweij J. New drugs for the treatment of sarcoma. Hematol. Oncol. Clin. N. Am.9, 909–925 (1995).
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol.26, 626–632 (2008).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist15, 300–307 (2010).
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Van Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different schedules. J. Clin. Oncol.27, 4188–4196 (2009).
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the primary endpoint for Phase II study in soft tissue sarcoma. Eur. J. Cancer38, 543–549 (2002).
   PubMed Web of Science ®Google Scholar
• Schöffski P, Dumez H, Wolter P et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin. Pharmacother.9(9), 1609–1618 (2008).
   PubMed Web of Science ®Google Scholar
• Van Oosterom AT, Mouridsen HT, Nielsen OS et al. Results of randomized studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur. J. Cancer38, 2397–2406 (2002).
   PubMed Web of Science ®Google Scholar
• Leahy M, Ray-Coquard I, Verweij J et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a Phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer43, 308–315 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Del Muro X, Lopez-Pousa A, Martin J et al. A Phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma. A study by the Spanish Group for Research on Sarcomas. Cancer104, 1706–1712 (2005).
   PubMedGoogle Scholar
• Hensley ML, Blessing JA, DeGeest K et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II study. Gynecol. Oncol.109, 23–28 (2008).
   Google Scholar
• Maki R, Watjhen JK, Patel SR et al. Randomized Phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J. Clin. Oncol.25, 2755–2763 (2007).
   PubMed Web of Science ®Google Scholar
• Losa R, Fra J, Lopez-Pousa A et al. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemother. Pharmacol.59, 251–259 (2007).
   PubMedGoogle Scholar
• Bailey HH, Mahoney MR, Ettinger DS et al. Phase II study of oral perifosine in patients with advanced soft tissue sarcoma. Cancer107, 2462–2467 (2006).
   PubMed Web of Science ®Google Scholar
• Penel N, Binh NB, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J. Clin. Oncol.26, 5269–5274 (2008).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Maki RG, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol.20, 2824–2831 (2002).
   PubMed Web of Science ®Google Scholar
• Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis13(1), 1–14 (2010).
   PubMed Web of Science ®Google Scholar
• Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist15, 539–547 (2010).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285, 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature407, 249–257 (2000).
   PubMed Web of Science ®Google Scholar
• Dirix LY, Vermeulen P, De Wever I, Van Oosterom AT. Soft tissue sarcoma in adults. Curr. Opin. Oncol.9, 348–359 (1997).
   PubMedGoogle Scholar
• Pakosi E, Goussia AC, Tsekerisi G, Papachristou DJ, Stefanou D, Agnantis NJ. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res.25, 3591–3596 (2005).
   PubMedGoogle Scholar
• DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer109(5), 813–819 (2007).
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Mostyn-Jones A, Koban MU, A’Hern R, Burton P, Thomas JM. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br. J. Surg.91, 242– 247 (2004).
   PubMed Web of Science ®Google Scholar
• Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) dependent signaling. FASEB J.16(11), 771–780 (2002).
   PubMed Web of Science ®Google Scholar
• Kilvaer TK, Valkov A, Sorbye S et al. Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS ONE5(12), E15368 (2010).
   PubMedGoogle Scholar
• Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal.19(10), 2003–2012 (2007).
   PubMed Web of Science ®Google Scholar
• Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocrine-Related Cancer8, 161–173 (2001).
   PubMed Web of Science ®Google Scholar
• Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc. Res.65, 550–563 (2005).
   PubMed Web of Science ®Google Scholar
• Wirzenius M, Tammela T, Uutela M et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J. Exp. Med.204, 1431–1440 (2007).
   PubMed Web of Science ®Google Scholar
• Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell. Biol.8, 464–478 (2007).
   PubMed Web of Science ®Google Scholar
• Karamysheva AF. Mechanisms of angiogenesis. Biochemistry (Mosc.)73, 751–762 (2008).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev.18, 4–25 (1997).
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell103, 211–225 (2000).
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N. Engl. J. Med.358, 2039–2049 (2008).
   PubMed Web of Science ®Google Scholar
• Distler JH, Hirth A, Kurowska-Stolarska M et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q. J. Nucl. Med.47, 149–161 (2003).
   PubMedGoogle Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer3, 401–410 (2003).
   PubMed Web of Science ®Google Scholar
• Kilvaer TK, Valkov A, Sorbye SW et al. Platelet-derived growth factors in non-GIST soft-tissue sarcomas identify a subgroup of patients with wide resection margins and poor disease-specific survival. Sarcoma2010, 751304 (2010).
   PubMedGoogle Scholar
• Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin. Cancer Res.13, 1098–1106 (2007).
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug. Disc.6, 734–745 (2007).
   PubMed Web of Science ®Google Scholar
• Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control14(3), 285–294 (2007).
   PubMedGoogle Scholar
• Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin. Investig. Drugs17, 253–261 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther.6, 2012–2021 (2007).
   PubMed Web of Science ®Google Scholar
• Shor AC, Agresta SV, D’Amato GZ, Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control15(1), 47–54 (2008).
   PubMedGoogle Scholar
• Hosaka S, Horiuchi K, Yoda M et al. A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K–AKT pathway. J. Orthop. Res. doi:10.1002/jor.22091 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Podar K, Tonon G, Sattler M et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA103(51), 19478–19483 (2006).
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res.15, 4220–4227 (2009).
   PubMed Web of Science ®Google Scholar
• Hutson TE, Davis ID, Machiels JP et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.28, 475–480 (2010).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol.28, 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Van Der Graaf WT, Blay J, Chawla SP et al. PALETTE: a randomized, double-blind, Phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy – an EORTC STBSG Global Network Study (EORTC 62072). J. Clin. Oncol.29(18 Suppl.), (2011) (Abstract LBA10002).
   PubMedGoogle Scholar
• Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol.22, 890–899 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol.22, 1480–1490 (2004).
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcoma: a European Organization for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J. Clin. Oncol.23, 576–584 (2005).
   PubMed Web of Science ®Google Scholar
• Schöffski P, Ray-Coquard IL, Cioffi A et al. European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a Phase 2 study in four independent histological subtypes. Lancet Oncol.12(11), 1045–1052 (2011).
   PubMed Web of Science ®Google Scholar